AU2023249795A1 - Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease - Google Patents

Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease Download PDF

Info

Publication number
AU2023249795A1
AU2023249795A1 AU2023249795A AU2023249795A AU2023249795A1 AU 2023249795 A1 AU2023249795 A1 AU 2023249795A1 AU 2023249795 A AU2023249795 A AU 2023249795A AU 2023249795 A AU2023249795 A AU 2023249795A AU 2023249795 A1 AU2023249795 A1 AU 2023249795A1
Authority
AU
Australia
Prior art keywords
compound
alkyl
cycloalkyl
heteroalkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023249795A
Other languages
English (en)
Inventor
Carolina BIGARELLA
Luca CARTA
Yaron R. HADARI
Rebecca HUTCHESON
Charles H. Reynolds
Michael Schmertzler
Theresa M. Williams
Sufang ZHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shy Therapeutics LLC
Original Assignee
Shy Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shy Therapeutics LLC filed Critical Shy Therapeutics LLC
Publication of AU2023249795A1 publication Critical patent/AU2023249795A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2023249795A 2022-04-08 2023-04-07 Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease Pending AU2023249795A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263329141P 2022-04-08 2022-04-08
US63/329,141 2022-04-08
US202263384905P 2022-11-23 2022-11-23
US63/384,905 2022-11-23
PCT/US2023/065530 WO2023196975A1 (en) 2022-04-08 2023-04-07 Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease

Publications (1)

Publication Number Publication Date
AU2023249795A1 true AU2023249795A1 (en) 2024-10-17

Family

ID=86270673

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023249795A Pending AU2023249795A1 (en) 2022-04-08 2023-04-07 Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease

Country Status (9)

Country Link
US (2) US12459951B2 (https=)
EP (1) EP4504341A1 (https=)
JP (1) JP2025512935A (https=)
KR (1) KR20250007533A (https=)
CN (1) CN119365460A (https=)
AU (1) AU2023249795A1 (https=)
CA (1) CA3246424A1 (https=)
IL (1) IL315733A (https=)
WO (1) WO2023196975A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4543886A1 (en) * 2022-06-23 2025-04-30 BioSplice Therapeutics, Inc. 4-alkoxypyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof
AU2024360599A1 (en) 2023-10-10 2026-04-09 Shy Therapeutics, Llc Pyrrolo[2,1-f][1,2,4]triazine compounds acting against cancers, inflammatory diseases, and fibrotic disease via interaction with ras superfamily proteins

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1273336A (en) 1986-04-25 1990-08-28 Chi-Ping Tseng Herbicidal heterocyclic carbonyl sulfonamides
US4838925A (en) 1986-04-25 1989-06-13 E. I. Du Pont De Nemours And Company Heterocyclic acyl sulfonamides
EP1669071B1 (en) 1999-05-21 2009-07-22 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
JP4649046B2 (ja) 1999-05-21 2011-03-09 ブリストル−マイヤーズ スクイブ カンパニー キナーゼのピロロトリアジン阻害剤
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
GEP20063915B (en) 2000-11-17 2006-09-11 Bristol Myers Squibb Co PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS
US6670357B2 (en) 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
TW200613306A (en) * 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1674467A1 (en) 2004-12-22 2006-06-28 4Sc Ag 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
US7576090B2 (en) 2004-12-27 2009-08-18 4Sc Ag Benzazole analogues and uses thereof
US7880004B2 (en) 2005-09-15 2011-02-01 Bristol-Myers Squibb Company Met kinase inhibitors
HRP20140688T1 (hr) 2006-07-07 2014-10-24 Bristol-Myers Squibb Company Inhibitori piroltriazin kinaze
US7531539B2 (en) * 2006-08-09 2009-05-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2008021859A1 (en) * 2006-08-09 2008-02-21 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
EP2134716A1 (en) 2007-04-18 2009-12-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JP2011513419A (ja) 2008-03-06 2011-04-28 ブリストル−マイヤーズ スクイブ カンパニー ピロロトリアジンキナーゼ阻害剤
WO2010002472A1 (en) 2008-07-02 2010-01-07 Ambit Biosciences Corporation Jak kinase modulating compounds and methods of use thereof
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
CN102245610B (zh) 2008-10-08 2014-04-30 百时美施贵宝公司 吡咯并三嗪激酶抑制剂
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
WO2011058109A1 (en) 2009-11-12 2011-05-19 Ucb Pharma S.A. Fused bicyclic pyrrole and imidazole derivatives as kinase inhibitors
US9073927B2 (en) 2010-01-22 2015-07-07 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Inhibitors of PI3 kinase
WO2011141713A1 (en) 2010-05-13 2011-11-17 Centro Nacional De Investigaciones Oncologicas (Cnio) New bicyclic compounds as pi3-k and mtor inhibitors
AU2011282241B2 (en) 2010-07-19 2015-07-30 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
BR112013008017A2 (pt) 2010-09-20 2016-06-14 Gilead Sciences Inc análogos de carba-nucleosídeo 2-flúor substituídos para tratamento antiviral
AU2013257018B2 (en) 2012-05-04 2017-02-16 Merck Patent Gmbh Pyrrolotriazinone derivatives
US9724352B2 (en) 2012-05-31 2017-08-08 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
CN102675323B (zh) 2012-06-01 2014-04-09 南京药石药物研发有限公司 吡咯并[2,1-f][1,2,4]三嗪衍生物及其抗肿瘤用途
EP2865671B1 (en) 2012-06-22 2017-11-01 Sumitomo Chemical Company, Ltd Fused heterocyclic compound
WO2014015523A1 (en) 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods
EP2938610A2 (en) 2012-12-28 2015-11-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
US20160089371A1 (en) 2013-03-15 2016-03-31 Intellikine, Llc Combination of Kinase Inhibitors and Uses Thereof
WO2015066371A1 (en) 2013-10-31 2015-05-07 Forum Pharmaceuticals, Inc. SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS
WO2015126808A2 (en) 2014-02-18 2015-08-27 Baldwin John J Hbv assay
CN104974163B (zh) 2014-04-14 2017-11-07 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
WO2016040764A1 (en) 2014-09-12 2016-03-17 Spero Therapeutics, Inc. Carbonyl linked bicyclic heteroaryl n-benzimidazoles and analogs as antibiotic tolerance inhibitors
WO2016119707A1 (en) 2015-01-29 2016-08-04 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods
WO2016190847A1 (en) 2015-05-26 2016-12-01 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
WO2017004134A1 (en) 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
JP2018520201A (ja) * 2015-07-23 2018-07-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｇｆベーター受容体アンタゴニスト
JP2018528951A (ja) 2015-08-31 2018-10-04 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＴＧＦβ受容体アンタゴニスト
ES2969565T3 (es) 2015-09-30 2024-12-13 Max Planck Ges Zur Foerderung Derwissenschaften E V Derivados heteroarílicos como inhibidores de la sepiapterina reductasa
WO2017070089A1 (en) 2015-10-19 2017-04-27 Incyte Corporation Heterocyclic compounds as immunomodulators
CN105534984A (zh) 2015-11-02 2016-05-04 广东中西达一新药开发有限公司 吡咯并三嗪类衍生物在预防或治疗乙肝病毒感染中的应用
CN105669680B (zh) 2016-03-24 2018-02-23 南京药捷安康生物科技有限公司 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂
KR102587382B1 (ko) 2016-04-29 2023-10-12 솔루스첨단소재 주식회사 유기 발광 화합물 및 이를 이용한 유기 전계 발광 소자
KR102288246B1 (ko) 2016-06-25 2021-08-10 수조우 킨터 제약회사(주) 라파마이신 신호전달 경로 저해제의 기계적 표적 및 이의 치료학적 적용
AU2017295863B2 (en) 2016-07-13 2022-07-07 Medic Life Sciences, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US20220041607A1 (en) 2016-08-17 2022-02-10 Shenzhen Targetrx, Inc. Fused bicyclic compound for inhibiting activity of tyrosine kinase
CN108276463A (zh) 2017-01-06 2018-07-13 米文君 一类新的化合物及其用途
CN108341819B (zh) 2017-01-22 2021-06-15 南京药捷安康生物科技有限公司 磷酸二酯酶抑制剂及其用途
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
AR112027A1 (es) 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
CN109111447A (zh) 2017-06-23 2019-01-01 中国科学院上海药物研究所 7-位取代吡咯并三嗪类化合物或其药学上可用的盐，及其制备方法和用途
JP7311228B2 (ja) 2017-06-30 2023-07-19 ベイジン タイド ファーマシューティカル カンパニー リミテッド Ｒｈｏ－関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
WO2019027765A1 (en) 2017-08-02 2019-02-07 Northwestern University SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS AND USES THEREOF
US20220054496A1 (en) 2018-09-13 2022-02-24 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncologicas Carlos III (F.S. Modulation of trf1 for brain cancer treatment
EP3867253A4 (en) 2018-10-16 2022-05-18 Ikena Oncology, Inc. Indole ahr inhibitors and uses thereof
AU2019387491A1 (en) 2018-11-30 2021-05-27 Celularity Inc. Expansion of natural killer cells and ILC3 cells with novel aromatic compounds
JP2022511457A (ja) 2018-11-30 2022-01-31 セルラリティ インク． 造血幹細胞および前駆細胞の活性化に使用するための芳香族化合物
WO2020119592A1 (zh) 2018-12-12 2020-06-18 信达生物制药(苏州)有限公司 一种新颖的三并环结构化合物及其制备方法和用途
CN112771048B (zh) 2018-12-19 2022-08-19 南京药石科技股份有限公司 流感病毒复制抑制剂及其中间体和用途
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
MX2021010319A (es) 2019-03-01 2021-12-10 Revolution Medicines Inc Compuestos biciclicos de heteroarilo y usos de estos.
US11760752B2 (en) 2019-03-21 2023-09-19 University Of Maryland, Baltimore Carboxylic acid, acyl sulfonamide and acyl sulfamide-derivatized bicyclic aza-heteroaromatics as selective Mcl-1 inhibitors and as dual Mcl-1/Bcl-2 inhibitors
CN111825675B (zh) 2019-04-15 2023-08-01 武汉朗来科技发展有限公司 Rock抑制剂及其制备方法和用途
WO2020210970A1 (en) 2019-04-16 2020-10-22 Bioardis Llc Imidazotriazine derivatives as cd73 inhibitors
CN112142744A (zh) 2019-06-28 2020-12-29 上海瑛派药业有限公司 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用
JP7557522B2 (ja) 2019-07-16 2024-09-27 オリック ファーマシューティカルズ，インク． Ｃｄ７３阻害剤
WO2021055747A1 (en) 2019-09-19 2021-03-25 Totus Medicines Inc. Therapeutic conjugates
PY2062527A (es) 2019-10-09 2021-09-23 Biocryst Pharm Inc Inhibidores del factor d del complemento para administración oral
WO2021094209A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
WO2021097299A1 (en) 2019-11-14 2021-05-20 Behavioral Diagnostics, Llc Methods and compositions for smoking cessation
PH12022551513A1 (en) * 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
JP2023513047A (ja) 2020-01-30 2023-03-30 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺有害生物的に有効な縮合二環式芳香族複素環式アミノ化合物
WO2021194927A1 (en) 2020-03-22 2021-09-30 Tlc Biopharmaceuticals, Inc. Composition of antiviral agent for use in prophylactic or post-exposure treatment of infectious or respiratory diseases
TW202204339A (zh) * 2020-03-31 2022-02-01 美商施萬生物製藥研發 Ip有限責任公司 經取代的嘧啶及使用方法
WO2021222807A1 (en) 2020-04-30 2021-11-04 Ajk Pharmaceutical Llc Fatty acyl and fatty ether conjugates of remdesivir and its active metabolites as antivirals
WO2022007966A1 (zh) * 2020-07-10 2022-01-13 四川海思科制药有限公司 Pb2抑制剂及其制备方法和用途
CN114105989A (zh) 2020-08-31 2022-03-01 中国科学院大连化学物理研究所 一种碘代吡咯并三嗪胺类化合物的制备方法和应用
CL2020003441A1 (es) * 2020-12-30 2021-04-30 Univ Tecnica Federico Santa Maria Utfsm Convertidor de potencia parcial dc-dc de topología controlable
WO2023027948A1 (en) 2021-08-21 2023-03-02 Relay Therapeutics, Inc. Jak2 inhibitors and methods of use thereof
WO2023110843A1 (en) 2021-12-15 2023-06-22 Almirall, S.A. Heterobicyclic derivatives as itk inhibitors
WO2023116865A1 (zh) 2021-12-23 2023-06-29 优领医药科技（上海）有限公司 含吡唑类衍生物、其药学上可接受的盐及其制备方法和应用
WO2023160572A1 (zh) 2022-02-24 2023-08-31 楚浦创制（武汉）医药科技有限公司 吡唑类衍生物、药物组合物及应用

Also Published As

Publication number Publication date
CN119365460A (zh) 2025-01-24
US12459951B2 (en) 2025-11-04
IL315733A (en) 2024-11-01
EP4504341A1 (en) 2025-02-12
KR20250007533A (ko) 2025-01-14
US20240360141A1 (en) 2024-10-31
JP2025512935A (ja) 2025-04-22
US20250289825A1 (en) 2025-09-18
WO2023196975A1 (en) 2023-10-12
CA3246424A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
AU2024360599A1 (en) Pyrrolo[2,1-f][1,2,4]triazine compounds acting against cancers, inflammatory diseases, and fibrotic disease via interaction with ras superfamily proteins
US11541041B1 (en) Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease
EP4389751A1 (en) Heterocyclic compounds and uses thereof
CN1323080C (zh) 具有抗增殖活性的嘧啶并化合物
WO2021121397A1 (zh) 取代的炔基杂环化合物
WO2021257828A9 (en) Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
JP2021514359A (ja) キナーゼ阻害剤としての複素環式化合物
JP7407461B2 (ja) がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
US12459951B2 (en) Compounds that interact with RAS superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
PT2086981E (pt) Compostos para inibir a progressão mitótica
JP2009512636A (ja) 細胞増殖抑制作用を有するイミダゾ［１，２−ａ］ピリジン類
CN120712259A (zh) 作为sos1抑制剂的唑基吡啶哒嗪酮酰胺
TW201514167A (zh) 二胺基雜芳基取代之吲唑
WO2019080723A1 (zh) 多取代吡啶酮类衍生物、其制备方法及其医药用途
WO2025011444A1 (zh) 一种嘧啶胺类nuak抑制剂及其制备方法和用途
CN113004282A (zh) 取代的炔基杂环化合物
CN118084935A (zh) 咪唑烷酮类化合物及其制备方法与应用
US20240309015A1 (en) Methods for the Treatment of Fibrotic Disease
US20240124483A1 (en) Methods for the Treatment of Fibrotic Disease
HK40104459A (en) Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
HK40029517B (en) Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
HK40029517A (en) Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
BR112019010617B1 (pt) Composto de oxoisoquinolina, seu uso e composição farmacêutica que o compreende